Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Delafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 12/20 | 0.40 |
| ▸ | TOP2B | Q02880 | 10/20 | 0.40 |
| ▸ | TOP1 | P11387 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delafloxacin SCHEMBL29356726 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL29379152 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL29631821 | 0.99 | CYP3A4 (0.85) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL441203 | 0.99 | CYP3A4 (0.85) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL7248671 | 0.96 | CYP3A4 (0.82) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL30626258 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL30626293 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL29080643 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL29080648 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL30593852 | 0.93 | CYP3A4 (0.75) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3919057-B1 | ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS | MELINTA SUBSIDIARY CORP (US) | 2026-01-28 | — | — | EP | claimed |
| US-12138257-B2 | Antimicrobial compositions | MELINTA SUBSIDIARY CORP. (US) | 2024-11-12 | — | — | US | claimed |
| EP-3766876-B1 | PHARMACEUTICAL FORMULATION CONTAINING A QUINOLONE DERIVATIVE | MELINTA SUBSIDIARY CORP (US) | 2023-09-13 | — | — | EP | claimed |
| US-20220265636-A1 | ANTIMICROBIAL COMPOSITIONS | MELINTA SUBSIDIARY CORP. | 2022-08-25 | — | — | US | claimed |
| EP-3957632-A1 | MEGLUMINE SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG (DELAFLOXACIN) | AbbVie Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| EP-3919057-A1 | ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS | Melinta Subsidiary Corp. (US) | 2021-12-08 | — | — | EP | claimed |
| EP-3056492-B1 | MEGLUMINE SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG (DELAFLOXACIN) | ABBVIE INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3581180-B1 | ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS | MELINTA SUBSIDIARY CORP (US) | 2021-08-04 | — | — | EP | claimed |
| EP-3766876-A1 | PHARMACEUTICAL FORMULATION CONTAINING A QUINOLONE DERIVATIVE | Melinta Subsidiary Corp. (US) | 2021-01-20 | — | — | EP | claimed |
| EP-3214083-B1 | PROCESS FOR MAKING QUINOLONE COMPOUNDS | MELINTA SUBSIDIARY CORP (US) | 2020-09-16 | — | — | EP | claimed |
| US-20070238719-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | RIB-X PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | claimed |
| US-20070238720-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | RIB-X PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | claimed |
| EP-1802607-A2 | SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG | ABBOTT LABORATORIES (US) | 2007-07-04 | — | — | EP | claimed |
| EP-1789392-A2 | PREPARATION OF PYRIDONECARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2007-05-30 | — | — | EP | claimed |
| US-20070043019-A1 | Salt and crystalline forms thereof of a drug | MELINTA SUBSIDIARY CORP. (F/K/A MELINTA THERAPEUTICS, INC.) | 2007-02-22 | — | — | US | claimed |
| WO-2006110815-A1 | PHARMACEUTICAL COMPOSITIONS HAVING IMPROVED DISSOLUTION PROFILES FOR POORLY SOLUBLE DRUGS | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | claimed |
| US-20060228411-A1 | Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs | ABBOTT LABORATORIES | 2006-10-12 | — | — | US | claimed |
| US-20060128686-A1 | reacting ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate and N-chlorosuccinimide, forming 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxlic acid | MELINTA SUBSIDIARY CORP. (F/K/A MELINTA THERAPEUTICS, INC.) | 2006-06-15 | — | — | US | claimed |
| WO-2006042034-A2 | SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG | ABBOTT LABORATORIES (US) | 2006-04-20 | — | — | WO | claimed |
| WO-2006015194-A2 | PREPARATION OF PYRIDONECARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2006-02-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238720-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | MMP8, CLPP, MASP2 | CYP3A4 1472/4885CYP2C9 833/4885ALDH1A1 1382/4885 |
| US-20220265636-A1 | ANTIMICROBIAL COMPOSITIONS | NOD2, QPCT, IFNG | CYP3A4 545/4885CYP2C9 402/4885ALDH1A1 2608/4885 |
| US-20060128686-A1 | reacting ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate and N-chlorosuccinimide, forming 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxlic acid | DHODH, QDPR, DDC | CYP3A4 153/4885CYP2C9 143/4885ALDH1A1 39/4885 |
| US-20070238719-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | MMP8, CLPP, MASP2 | CYP3A4 1472/4885CYP2C9 833/4885ALDH1A1 1382/4885 |
| US-12138257-B2 | Antimicrobial compositions | NOD2, QPCT, IFNG | CYP3A4 545/4885CYP2C9 402/4885ALDH1A1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.